1 1290 106 DECODING THE GENETIC AND EPIGENETIC BASIS OF ASTHMA. ASTHMA IS A COMPLEX AND HETEROGENEOUS CHRONIC INFLAMMATORY DISEASE OF THE AIRWAYS. ALONGSIDE ENVIRONMENTAL FACTORS, ASTHMA SUSCEPTIBILITY IS STRONGLY INFLUENCED BY GENETICS. GIVEN ITS HIGH PREVALENCE AND OUR INCOMPLETE UNDERSTANDING OF THE MECHANISMS UNDERLYING DISEASE SUSCEPTIBILITY, ASTHMA IS FREQUENTLY STUDIED IN GENOME-WIDE ASSOCIATION STUDIES (GWAS), WHICH HAVE IDENTIFIED THOUSANDS OF GENETIC VARIANTS ASSOCIATED WITH ASTHMA DEVELOPMENT. VIRTUALLY ALL THESE GENETIC VARIANTS RESIDE IN NON-CODING GENOMIC REGIONS, WHICH HAS OBSCURED THE FUNCTIONAL IMPACT OF ASTHMA-ASSOCIATED VARIANTS AND THEIR TRANSLATION INTO DISEASE-RELEVANT MECHANISMS. RECENT ADVANCES IN GENOMICS TECHNOLOGY AND EPIGENETICS NOW OFFER METHODS TO LINK GENETIC VARIANTS TO GENE REGULATORY ELEMENTS EMBEDDED WITHIN NON-CODING REGIONS, WHICH HAVE STARTED TO UNRAVEL THE MOLECULAR MECHANISMS UNDERLYING THE COMPLEX (EPI)GENETICS OF ASTHMA. HERE, WE PROVIDE AN INTEGRATED OVERVIEW OF (EPI)GENETIC VARIANTS ASSOCIATED WITH ASTHMA, FOCUSING ON EFFORTS TO LINK THESE DISEASE ASSOCIATIONS TO BIOLOGICAL INSIGHT INTO ASTHMA PATHOPHYSIOLOGY USING STATE-OF-THE-ART GENOMICS METHODOLOGY. FINALLY, WE PROVIDE A PERSPECTIVE AS TO HOW DECODING THE GENETIC AND EPIGENETIC BASIS OF ASTHMA HAS THE POTENTIAL TO TRANSFORM CLINICAL MANAGEMENT OF ASTHMA AND TO PREDICT THE RISK OF ASTHMA DEVELOPMENT. 2023 2 5544 23 ROLE OF EPIGENETIC ABNORMALITIES AND INTERVENTION IN OBSTRUCTIVE SLEEP APNEA TARGET ORGANS. OBSTRUCTIVE SLEEP APNEA (OSA) IS A COMMON CONDITION THAT HAS CONSIDERABLE IMPACTS ON HUMAN HEALTH. EPIGENETICS HAS BECOME A RAPIDLY DEVELOPING AND EXCITING AREA IN BIOLOGY, AND IT IS DEFINED AS HERITABLE ALTERATIONS IN GENE EXPRESSION AND HAS REGULATORY EFFECTS ON DISEASE PROGRESSION. HOWEVER, THE PUBLISHED LITERATURE THAT IS INTEGRATING BOTH OF THEM IS NOT SUFFICIENT. THE PURPOSE OF THIS ARTICLE IS TO EXPLORE THE RELATIONSHIP BETWEEN OSA AND EPIGENETICS AND TO OFFER BETTER DIAGNOSTIC METHODS AND TREATMENT OPTIONS. EPIGENETIC MODIFICATIONS MAINLY MANIFEST AS POST-TRANSLATIONAL MODIFICATIONS IN DNA AND HISTONE PROTEINS AND REGULATION OF NON-CODING RNAS. CHRONIC INTERMITTENT HYPOXIA-MEDIATED EPIGENETIC ALTERATIONS ARE INVOLVED IN THE PROGRESSION OF OSA AND DIVERSE MULTIORGAN INJURIES, INCLUDING CARDIOVASCULAR DISEASE, METABOLIC DISORDERS, PULMONARY HYPERTENSION, NEURAL DYSFUNCTION, AND EVEN TUMORS. THIS ARTICLE PROVIDES DEEPER INSIGHTS INTO THE DISEASE MECHANISM OF OSA AND POTENTIAL APPLICATIONS OF TARGETED DIAGNOSIS, TREATMENT, AND PROGNOSIS IN OSA COMPLICATIONS. 2023 3 5256 38 PROGRESSES IN EPIGENETIC STUDIES OF ASTHMA FROM THE PERSPECTIVE OF HIGH-THROUGHPUT ANALYSIS TECHNOLOGIES: A NARRATIVE REVIEW. BACKGROUND AND OBJECTIVE: ASTHMA IS THE MOST COMMON CHRONIC RESPIRATORY DISEASE IN THE WORLD WITH AN ESTIMATED HERITABILITY BETWEEN 50% AND 60%, AND RECENT STUDIES HAVE SHOWN THAT EPIGENETIC MECHANISMS PLAY AN IMPORTANT ROLE IN ITS DEVELOPMENT. MANY CUTTING-EDGE EPIGENETIC RESEARCH TECHNIQUES HAVE BEEN APPLIED TO THE STUDY OF THE PATHOGENESIS OF ASTHMA, WHICH HAS PROMOTED THE DEVELOPMENT OF ASTHMA ETIOLOGY AND BROUGHT NEW POSSIBILITIES FOR TREATMENT. WE SUMMARIZED RECENT ADVANCES IN EPIGENETIC RESEARCH OF THE PATHOGENESIS OF ASTHMA, ESPECIALLY FROM THE PERSPECTIVE OF HIGH-THROUGHPUT ANALYSIS TECHNIQUES, TO FIND POTENTIAL EPIGENETIC BIOMARKERS AND POSSIBLE MOLECULAR TARGETS FOR THE FUTURE INTERVENTION AND TREATMENT OF THE DISEASE. METHODS: WE REVIEWED AND SUMMARIZED RECENT PROGRESS IN EPIGENOMIC STUDIES OF ASTHMA ON A "PRE-TRANSCRIPTIONAL LEVEL", INCLUDING DNA METHYLATION, HISTONE MODIFICATION, AND CHROMATIN REMODELING, AND ON A "POST-TRANSCRIPTIONAL LEVEL" WITH A FOCUS ON NON-CODING RNA, FROM THE PERSPECTIVE OF HIGH-THROUGHPUT ANALYSIS TECHNOLOGIES. KEY CONTENT AND FINDINGS: WE HAVE SUMMARIZED THE PROGRESS OF DIFFERENT KINDS OF RECENT EPIGENETIC STUDIES IN ASTHMA, INCLUDING DNA METHYLATION STUDIES [CANDIDATE GENES METHYLATION STUDIES AND EPIGENOME-WIDE ASSOCIATION STUDY (EWAS)], HISTONE MODIFICATION STUDIES (HISTONE ACETYLATION/DEACETYLATION STUDIES AND HISTONE METHYLATION STUDIES), NON-CODING RNA STUDIES [MICRORNAS (MIRNAS), LONG NON-CODING RNAS (LNCRNAS) AND CIRCULAR RNAS (CIRCRNAS)], TO HELP THE READERS TO GAIN A COMPREHENSIVE INSIGHT INTO THE EPIGENETIC RESEARCH FIELDS FOR ASTHMA. THE APPLICATION OF HIGH-THROUGHPUT ANALYSIS TECHNIQUES IN ASTHMA RESEARCH, INCLUDING EWAS (DNA METHYLATION CHIPS), CHROMATIN IMMUNOPRECIPITATION SEQUENCING (CHIP-SEQ), MICRORNA SEQUENCING, WHOLE TRANSCRIPTOME SEQUENCING, CO-EXPRESSION NETWORK AND COMPETING ENDOGENOUS RNA (CERNA) ANALYSES, WERE INTRODUCED ACCOMPANY WITH THE MAIN FINDINGS. AND THE POTENTIAL EPIGENETIC BIOMARKERS AND POSSIBLE MOLECULAR TARGETS IDENTIFIED VIA HIGH-THROUGHPUT ANALYSES WERE ALSO DISCUSSED. CONCLUSIONS: EPIGENETIC RESEARCH HAS BECOME A HOTSPOT IN RESEARCH ON THE PATHOGENESIS OF ASTHMA. THE COMBINATION OF HIGH-THROUGHPUT EPIGENETIC ANALYSIS TECHNOLOGIES AND TRADITIONAL BIOLOGICAL FUNCTION AND CLINICAL STUDIES WILL BRING NEW BREAKTHROUGH IN THE PATHOGENESIS STUDY OF ASTHMA, WHICH WILL IMPROVE THE GENETIC INTERPRETATION OF THE DISEASE AND BRING MORE POSSIBILITIES FOR THE DEVELOPMENT OF PRECISION MEDICINE TO TREAT IT. 2022 4 3027 30 GENETICS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IS A COMPLEX DISEASE WITH MULTIFACTORIAL BACKGROUND, BASED ON THE INTERACTION OF ENVIRONMENTAL AND GENETIC FACTORS. ENVIRONMENTAL FACTORS ARE CLEARLY RELATED TO THE DEVELOPMENT OF THE DISEASE. HOWEVER, FAMILY AND TWIN STUDIES SUGGESTED GENETICS FACTORS TO BE ONE OF THE IMPORTANT DETERMINANTS FOR THE DEVELOPMENT OF COPD. DIFFERENT APPROACHES HAVE BEEN USED TO IDENTIFY GENES OF INTEREST. GENOMEWIDE LINKAGE ANALYSIS FOUND AREAS OF INTEREST ON DIFFERENT CHROMOSOMES, WITH SOME GENES LOCATED IN THIS REGIONS BEING IDENTIFIED AND REPLICATED AS SUSCEPTIBILITY GENES. NUMEROUS OF CANDIDATE GENES THAT COULD BE LINKED TO DISEASE PATHOGENESIS HAVE BEEN IMPLICATED IN COPD GENETICS. HOWEVER, THE CANDIDATE GENE APPROACH IS OFTEN LIMITED BY INCONSISTENT RESULTS IN OTHER STUDY POPULATIONS. RECENTLY, A COMBINATION OF DIFFERENT METHODS IS USED GIVING MORE EVIDENCE FOR SOME CANDIDATE GENES, INCLUDING TGFBETA-1, SURFACTANT, SERPINE2 AND MICROSOMAL EPOXIDE HYDROLASE. IN THE FUTURE ONGOING EXACT PHENOTYPE DEFINITION, COMBINATION OF SEVERAL APPROACHES, GENOME-WIDE ASSOCIATION STUDIES AND ANIMAL MODEL GENETICS WILL LEAD TO NEW INSIGHTS INTO THE GENETICS OF COPD, WITH EPIGENETIC FACTORS NEEDS TO BE FURTHER INVESTIGATED AND CONSIDERED IN CONCERT WITH GENETIC FINDINGS. 2007 5 2929 16 GENES AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE. ALTHOUGH MUCH REMAINS TO BE DONE, RECENT ADVANCES AND THE ADVENT OF NEW METHODOLOGIES ARE PROMISING AND SHOULD YIELD INCREASED UNDERSTANDING OF THE GENETIC AND EPIGENETIC MECHANISMS INFLUENCING THE PATHOGENESIS OF COPD, BOTH RELATED AND UNRELATED TO SEVERE AAT DEFICIENCY. SUCH UNDERSTANDING SHOULD ULTIMATELY BE TRANSLATED INTO NOVEL APPROACHES TO PREVENT, DIAGNOSE, AND TREAT COPD. 2012 6 2599 36 EPIGENETICS OF THE VASCULAR ENDOTHELIUM. CLASSICAL MODELS OF TRANSCRIPTION IN VASCULAR ENDOTHELIAL CELLS, SPECIFICALLY THE CIS/TRANS PARADIGM, HAVE LIMITATIONS. FOR INSTANCE, HOW DOES THE ENVIRONMENT HAVE CHRONIC EFFECTS ON GENE EXPRESSION IN ENDOTHELIAL CELLS AFTER WEEKS OR YEARS? WHEN AN ENDOTHELIAL CELL DIVIDES, HOW IS THIS INFORMATION TRANSMITTED TO DAUGHTER CELLS? EPIGENETICS REFERS TO CHROMATIN-BASED PATHWAYS IMPORTANT IN THE REGULATION OF GENE EXPRESSION AND INCLUDES THREE DISTINCT, BUT HIGHLY INTERRELATED, MECHANISMS: DNA METHYLATION, HISTONE DENSITY AND POSTTRANSLATIONAL MODIFICATIONS, AND RNA-BASED MECHANISMS. TOGETHER THEY OFFER A NEWER PERSPECTIVE ON TRANSCRIPTIONAL CONTROL PARADIGMS IN VASCULAR ENDOTHELIAL CELLS AND PROVIDE A MOLECULAR BASIS FOR UNDERSTANDING HOW THE ENVIRONMENT IMPACTS THE GENOME TO MODIFY DISEASE SUSCEPTIBILITY. THIS ALTERNATIVE VIEWPOINT FOR TRANSCRIPTIONAL REGULATION ALLOWS A REASSESSMENT OF THE CIS/TRANS MODEL AND EVEN HELPS EXPLAIN SOME OF ITS LIMITATIONS. THIS REVIEW PROVIDES AN INTRODUCTION TO EPIGENETIC CONCEPTS FOR VASCULAR BIOLOGISTS AND USES TOPICAL EXAMPLES IN CELL BIOLOGY TO PROVIDE INSIGHT INTO HOW CELL TYPES OR EVEN WHOLE ORGANISMS, SUCH AS MONOZYGOTIC HUMAN TWINS WITH THE SAME DNA SEQUENCE, CAN EXHIBIT HETEROGENEOUS PATTERNS OF GENE EXPRESSION, PHENOTYPE, OR DISEASES PREVALENCE. USING ENDOTHELIAL NITRIC OXIDE SYNTHASE (NOS3) AS AN EXAMPLE, WE EXAMINE THE GROWING BODY OF EVIDENCE IMPLICATING EPIGENETIC PATHWAYS IN THE CONTROL OF VASCULAR ENDOTHELIAL GENE EXPRESSION IN HEALTH AND DISEASE. 2010 7 6244 30 THE MECHANISMS OF HSC ACTIVATION AND EPIGENETIC REGULATION OF HSCS PHENOTYPES. EPIGENETICS IS A DYNAMICALLY EXPANDING FIELD OF SCIENCE ENTAILING NUMEROUS REGULATORY MECHANISMS CONTROLLING CHANGES OF GENE EXPRESSION IN RESPONSE TO ENVIRONMENTAL FACTORS. OVER THE RECENT YEARS THERE HAS BEEN A GREAT INTEREST IN EPIGENETIC MARKS AS A POTENTIAL DIAGNOSTIC AND PROGNOSTIC TOOL OR FUTURE TARGET FOR TREATMENT OF VARIOUS HUMAN DISEASES. THERE IS AN INCREASING BODY OF PUBLISHED RESEARCH TO SUGGEST THAT EPIGENETIC EVENTS REGULATE PROGRESSION OF CHRONIC LIVER DISEASE. EXPERIMENTAL MANIPULATION OF EPIGENETIC SIGNATURES SUCH AS DNA METHYLATION, HISTONE ACETYLATION / METHYLATION AND THE ACTIVITIES OF PROTEINS THAT EITHER ANNOTATE OR INTERPRET THESE EPIGENETIC MARKS CAN HAVE PROFOUND EFFECTS ON THE ACTIVATION AND PHENOTYPE OF HSC, KEY CELLS RESPONSIBLE FOR ONSET AND PROGRESSION OF LIVER FIBROSIS. THIS REVIEW PRESENTS RECENT ADVANCES IN EPIGENETIC ALTERATIONS, WHICH COULD PROVIDE MECHANISTIC INSIGHT INTO THE PATHOGENESIS OF CHRONIC LIVER DISEASE AND PROVIDE NOVEL CLINICAL APPLICATIONS. 2014 8 5299 40 PROTEIN INTERACTION NETWORKS PROVIDE INSIGHT INTO FETAL ORIGINS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. BACKGROUND: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IS A LEADING CAUSE OF DEATH IN ADULTS THAT MAY HAVE ORIGINS IN EARLY LUNG DEVELOPMENT. IT IS A COMPLEX DISEASE, INFLUENCED BY MULTIPLE FACTORS INCLUDING GENETIC VARIANTS AND ENVIRONMENTAL FACTORS. MATERNAL SMOKING DURING PREGNANCY MAY INFLUENCE THE RISK FOR DISEASES DURING ADULTHOOD, POTENTIALLY THROUGH EPIGENETIC MODIFICATIONS INCLUDING METHYLATION. METHODS: IN THIS WORK, WE EXPLORE THE FETAL ORIGINS OF COPD BY UTILIZING LUNG DNA METHYLATION MARKS ASSOCIATED WITH IN UTERO SMOKE (IUS) EXPOSURE, AND EVALUATE THE NETWORK RELATIONSHIPS BETWEEN METHYLOMIC AND TRANSCRIPTOMIC SIGNATURES ASSOCIATED WITH ADULT LUNG TISSUE FROM FORMER SMOKERS WITH AND WITHOUT COPD. TO IDENTIFY POTENTIAL PATHOBIOLOGICAL MECHANISMS THAT MAY LINK FETAL LUNG, SMOKE EXPOSURE AND ADULT LUNG DISEASE, WE STUDY THE INTERACTIONS (PHYSICAL AND FUNCTIONAL) OF IDENTIFIED GENES USING PROTEIN-PROTEIN INTERACTION NETWORKS. RESULTS: WE BUILD IUS-EXPOSURE AND COPD MODULES, WHICH IDENTIFY CONNECTED SUBNETWORKS LINKING FETAL LUNG SMOKE EXPOSURE TO ADULT COPD. STUDYING THE RELATIONSHIPS AND CONNECTIVITY AMONG THE DIFFERENT MODULES FOR FETAL SMOKE EXPOSURE AND ADULT COPD, WE IDENTIFY ENRICHED PATHWAYS, INCLUDING THE AGE-RAGE AND FOCAL ADHESION PATHWAYS. CONCLUSIONS: THE MODULES IDENTIFIED IN OUR ANALYSIS ADD NEW AND POTENTIALLY IMPORTANT INSIGHTS TO UNDERSTANDING THE EARLY LIFE MOLECULAR PERTURBATIONS RELATED TO THE PATHOGENESIS OF COPD. WE IDENTIFY AGE-RAGE AND FOCAL ADHESION AS TWO BIOLOGICALLY PLAUSIBLE PATHWAYS THAT MAY REVEAL LUNG DEVELOPMENTAL CONTRIBUTIONS TO COPD. WE WERE NOT ONLY ABLE TO IDENTIFY MEANINGFUL MODULES BUT WERE ALSO ABLE TO STUDY INTERCONNECTIONS BETWEEN SMOKE EXPOSURE AND LUNG DISEASE, AUGMENTING OUR KNOWLEDGE ABOUT THE FETAL ORIGINS OF COPD. 2022 9 2531 29 EPIGENETICS IN ASTHMA. PURPOSE OF REVIEW: ASTHMA IS ONE OF THE MOST COMMON CHRONIC RESPIRATORY DISEASES LINKED WITH INCREASED MORBIDITY AND HEALTHCARE UTILIZATION. THE UNDERLYING PATHOPHYSIOLOGICAL PROCESSES AND CAUSAL RELATIONSHIPS OF ASTHMA WITH EPIGENETIC MECHANISMS ARE PARTIALLY UNDERSTOOD. HERE WE REVIEW HUMAN STUDIES OF EPIGENETIC MECHANISMS IN ASTHMA, WITH A SPECIAL FOCUS ON DNA METHYLATION. RECENT FINDINGS: EPIGENETIC STUDIES OF CHILDHOOD ASTHMA HAVE IDENTIFIED SPECIFIC METHYLATION SIGNATURES ASSOCIATED WITH ALLERGIC INFLAMMATION IN THE AIRWAY AND IMMUNE CELLS, DEMONSTRATING A REGULATORY ROLE FOR METHYLATION IN ASTHMA PATHOGENESIS. DESPITE THESE NOVEL FINDINGS, ADDITIONAL RESEARCH IN THE ROLE OF EPIGENETIC MECHANISMS UNDERLYING ASTHMA ENDOTYPES IS NEEDED. SIMILARLY, STUDIES OF HISTONE MODIFICATIONS ARE ALSO LACKING IN ASTHMA. FUTURE STUDIES OF EPIGENETIC MECHANISMS IN ASTHMA WILL BENEFIT FROM DATA INTEGRATION IN WELL PHENOTYPED COHORTS. THIS REVIEW PROVIDES AN OVERVIEW OF THE CURRENT LITERATURE ON EPIGENETIC STUDIES IN HUMAN ASTHMA, WITH SPECIAL EMPHASIS ON METHYLATION AND CHILDHOOD ASTHMA. 2019 10 2642 29 EPIGENOMIC AND TRANSCRIPTOMIC ANALYSIS OF CHRONIC INFLAMMATORY DISEASES. CHRONIC INFLAMMATORY DISEASES (CIDS) HAVE COMPLEX PATHOLOGIES THAT RESULT FROM ABERRANT AND PERSISTENT IMMUNE RESPONSES. HOWEVER, THE PRECISE TRIGGERS AND MECHANISMS REMAIN ELUSIVE. AN IMPORTANT ASPECT OF CID RESEARCH FOCUSES ON EPIGENETICS MODIFICATIONS, WHICH REGULATE GENE EXPRESSION AND PROVIDE A DYNAMIC TRANSCRIPTIONAL RESPONSE TO INFLAMMATION. IN RECENT YEARS, MOUNTING EVIDENCE HAS DEMONSTRATED AN ASSOCIATION BETWEEN EPIGENOMIC AND TRANSCRIPTOMIC DYSREGULATION AND THE PHENOTYPES OF CIDS. IN PARTICULAR, EPIGENETIC CHANGES AT CIS-REGULATORY ELEMENTS HAVE PROVIDED NEW INSIGHTS FOR IMMUNE CELL-SPECIFIC ALTERATIONS THAT CONTRIBUTE TO DISEASE ETIOLOGY. FURTHERMORE, THE ADVANCEMENTS IN SINGLE-CELL GENOMICS PROVIDE NOVEL SOLUTIONS TO CELL TYPE HETEROGENEITY, WHICH HAS LONG POSED CHALLENGES FOR CID DIAGNOSIS AND TREATMENT. IN THIS REVIEW, WE DISCUSS THE CURRENT STATE OF EPIGENOMICS RESEARCH OF CID AND THE INSIGHTS DERIVED FROM SINGLE-CELL TRANSCRIPTOMIC AND EPIGENOMIC STUDIES. 2021 11 6735 34 WHAT HAVE MECHANISTIC STUDIES TAUGHT US ABOUT CHILDHOOD ASTHMA? CHILDHOOD ASTHMA IS A CHRONIC HETEROGENEOUS SYNDROME CONSISTING OF DIFFERENT DISEASE ENTITIES OR PHENOTYPES. THE IMMUNOLOGIC AND CELLULAR PROCESSES THAT OCCUR DURING ASTHMA DEVELOPMENT ARE STILL NOT FULLY UNDERSTOOD BUT REPRESENT DISTINCT ENDOTYPES. MECHANISTIC STUDIES HAVE EXAMINED THE ROLE OF GENE EXPRESSION, PROTEIN LEVELS, AND CELL TYPES IN EARLY LIFE DEVELOPMENT AND THE MANIFESTATION OF ASTHMA, MANY UNDER THE INFLUENCE OF ENVIRONMENTAL STIMULI, WHICH CAN BE BOTH PROTECTIVE AND RISK FACTORS FOR ASTHMA. GENETIC VARIANTS CAN REGULATE GENE EXPRESSION, CONTROLLED PARTLY BY DIFFERENT EPIGENETIC MECHANISMS. IN ADDITION, ENVIRONMENTAL FACTORS, SUCH AS LIVING SPACE, NUTRITION, AND SMOKING, CAN CONTRIBUTE TO THESE MECHANISMS. ALL OF THESE FACTORS PRODUCE MODIFICATIONS IN GENE EXPRESSION THAT CAN ALTER THE DEVELOPMENT AND FUNCTION OF IMMUNE AND EPITHELIAL CELLS AND SUBSEQUENTLY DIFFERENT TRAJECTORIES OF CHILDHOOD ASTHMA. THESE EARLY CHANGES IN A PARTIALLY IMMATURE IMMUNE SYSTEM CAN HAVE DRAMATIC EFFECTS (E.G., CAUSING DYSREGULATION), WHICH IN TURN CONTRIBUTE TO DIFFERENT DISEASE ENDOTYPES AND MAY HELP TO EXPLAIN DIFFERENTIAL RESPONSIVENESS TO ASTHMA TREATMENT. IN THIS REVIEW, WE SUMMARIZE PUBLISHED STUDIES THAT HAVE AIMED TO UNCOVER DISTINCT MECHANISMS IN CHILDHOOD ASTHMA, CONSIDERING GENETICS, EPIGENETICS, AND ENVIRONMENT. MOREOVER, A DISCUSSION OF NEW, POWERFUL TOOLS FOR SINGLE-CELL IMMUNOLOGIC ASSAYS FOR PHENOTYPIC AND FUNCTIONAL ANALYSIS IS INCLUDED, WHICH PROMISE NEW MECHANISTIC INSIGHTS INTO CHILDHOOD ASTHMA DEVELOPMENT AND THERAPEUTIC AND PREVENTIVE STRATEGIES. 2023 12 3706 41 INFLUENCE OF GENETICS ON DISEASE SUSCEPTIBILITY AND PROGRESSION. FOR MANY CHRONIC DISEASES, THE INFLUENCE OF GENETICS IS COMPLEX AND PHENOTYPES DO NOT CONFORM TO SIMPLE MENDELIAN PATTERNS OF INHERITANCE. DISCUSSED HERE ARE TWO TYPES OF GENETIC INFLUENCES ON HEALTHY AGING. THE FIRST INVOLVES VARIATION IN THE GENE SEQUENCE ITSELF AND HOW THIS MAY INFLUENCE DISEASE SUSCEPTIBILITY, PROGRESSION, AND SEVERITY, INTERACTING WITH OTHER RECOGNIZED RISK FACTORS. THE SECOND INVOLVES EPIGENETIC REGULATORY MECHANISMS THAT MAY POTENTIALLY PROVIDE INSIGHT INTO HOW ENVIRONMENTAL INFLUENCES AFFECT THE EXPRESSED GENOME, THUS IMPROVING OUR UNDERSTANDING OF THE GENETIC MECHANISMS UNDERLYING MULTIFACTORIAL DISEASES. THE INTERLEUKIN-1 FAMILY OF CYTOKINES CAN BE USED TO ILLUSTRATE HOW GENETIC SEQUENCE VARIATION MAY AFFECT SUCH DISEASES. THIS CYTOKINE FAMILY PLAYS A KEY ROLE IN MEDIATING INFLAMMATION, WHICH IS NOW UNDERSTOOD TO BE A CENTRAL COMPONENT OF A GROWING NUMBER OF CHRONIC DISEASES. RECENT WORK HAS REVEALED MANY SEQUENCE VARIATIONS IN THE REGULATORY DNA OF GENES ENCODING IMPORTANT MEMBERS OF THE INTERLEUKIN-1 FAMILY, AND THESE VARIATIONS ARE ASSOCIATED WITH DIFFERENTIAL EFFECTS ON THE INFLAMMATORY RESPONSE. THE INTERACTIONS OF ENVIRONMENTAL FACTORS WITH BOTH DNA SEQUENCE VARIATIONS AND EPIGENETIC MODIFICATIONS ARE LIKELY TO DETERMINE THE PHENOTYPES OF MULTIFACTORIAL DISEASES OF AGING AS WELL AS THE PHENOTYPE OF HEALTHY AGING. 2007 13 2330 32 EPIGENETIC REGULATION OF IMMUNE FUNCTION IN ASTHMA. ASTHMA IS A COMMON COMPLEX RESPIRATORY DISEASE CHARACTERIZED BY CHRONIC AIRWAY INFLAMMATION AND PARTIALLY REVERSIBLE AIRFLOW OBSTRUCTION RESULTING FROM GENETIC AND ENVIRONMENTAL DETERMINANTS. BECAUSE EPIGENETIC MARKS INFLUENCE GENE EXPRESSION AND CAN BE MODIFIED BY BOTH ENVIRONMENTAL EXPOSURES AND GENETIC VARIATION, THEY ARE INCREASINGLY RECOGNIZED AS RELEVANT TO THE PATHOGENESIS OF ASTHMA AND MAY BE A KEY LINK BETWEEN ENVIRONMENTAL EXPOSURES AND ASTHMA SUSCEPTIBILITY. UNLIKE CHANGES TO DNA SEQUENCE, EPIGENETIC SIGNATURES ARE DYNAMIC AND REVERSIBLE, CREATING AN OPPORTUNITY FOR NOT ONLY THERAPEUTIC TARGETS BUT MAY SERVE AS BIOMARKERS TO FOLLOW DISEASE COURSE AND IDENTIFY MOLECULAR SUBTYPES IN HETEROGENEOUS DISEASES SUCH AS ASTHMA. IN THIS REVIEW, WE WILL EXAMINE THE RELATIONSHIP BETWEEN ASTHMA AND 3 KEY EPIGENETIC PROCESSES THAT MODIFY GENE EXPRESSION: DNA METHYLATION, MODIFICATION OF HISTONE TAILS, AND NONCODING RNAS. IN ADDITION TO PRESENTING A COMPREHENSIVE ASSESSMENT OF THE EXISTING EPIGENETIC STUDIES FOCUSING ON IMMUNE REGULATION IN ASTHMA, WE WILL DISCUSS FUTURE DIRECTIONS FOR EPIGENETIC INVESTIGATION IN ALLERGIC AIRWAY DISEASE. 2022 14 6414 38 THE STRESSED SYNAPSE 2.0: PATHOPHYSIOLOGICAL MECHANISMS IN STRESS-RELATED NEUROPSYCHIATRIC DISORDERS. STRESS IS A PRIMARY RISK FACTOR FOR SEVERAL NEUROPSYCHIATRIC DISORDERS. EVIDENCE FROM PRECLINICAL MODELS AND CLINICAL STUDIES OF DEPRESSION HAVE REVEALED AN ARRAY OF STRUCTURAL AND FUNCTIONAL MALADAPTIVE CHANGES, WHEREBY ADVERSE ENVIRONMENTAL FACTORS SHAPE THE BRAIN. THESE CHANGES, OBSERVED FROM THE MOLECULAR AND TRANSCRIPTIONAL LEVELS THROUGH TO LARGE-SCALE BRAIN NETWORKS, TO THE BEHAVIOURS REVEAL A COMPLEX MATRIX OF INTERRELATED PATHOPHYSIOLOGICAL PROCESSES THAT DIFFER BETWEEN SEXES, PROVIDING INSIGHT INTO THE POTENTIAL UNDERPINNINGS OF THE SEX BIAS OF NEUROPSYCHIATRIC DISORDERS. ALTHOUGH MANY PRECLINICAL STUDIES USE CHRONIC STRESS PROTOCOLS, LONG-TERM CHANGES ARE ALSO INDUCED BY ACUTE EXPOSURE TO TRAUMATIC STRESS, OPENING A PATH TO IDENTIFY DETERMINANTS OF RESILIENT VERSUS SUSCEPTIBLE RESPONSES TO BOTH ACUTE AND CHRONIC STRESS. EPIGENETIC REGULATION OF GENE EXPRESSION HAS EMERGED AS A KEY PLAYER UNDERLYING THE PERSISTENT IMPACT OF STRESS ON THE BRAIN. INDEED, HISTONE MODIFICATION, DNA METHYLATION AND MICRORNAS ARE CLOSELY INVOLVED IN MANY ASPECTS OF THE STRESS RESPONSE AND REVEAL THE GLUTAMATE SYSTEM AS A KEY PLAYER. THE SUCCESS OF KETAMINE HAS STIMULATED A WHOLE LINE OF RESEARCH AND DEVELOPMENT ON DRUGS DIRECTLY OR INDIRECTLY TARGETING GLUTAMATE FUNCTION. HOWEVER, THE CHALLENGE OF TRANSLATING THE EMERGING UNDERSTANDING OF STRESS PATHOPHYSIOLOGY INTO EFFECTIVE CLINICAL TREATMENTS REMAINS A MAJOR CHALLENGE. 2022 15 3404 35 HOW EPIGENETICS IMPACTS ON HUMAN DISEASES. EPIGENETICS IS A RAPIDLY GROWING FIELD OF BIOLOGY THAT STUDIES THE CHANGES IN GENE EXPRESSION THAT ARE NOT DUE TO ALTERATIONS IN THE DNA SEQUENCE BUT RATHER THE CHEMICAL MODIFICATIONS OF DNA AND ITS ASSOCIATED PROTEINS. EPIGENETIC MECHANISMS CAN PROFOUNDLY INFLUENCE GENE EXPRESSION, CELL DIFFERENTIATION, TISSUE DEVELOPMENT, AND DISEASE SUSCEPTIBILITY. UNDERSTANDING EPIGENETIC CHANGES IS ESSENTIAL TO ELUCIDATE THE MECHANISMS UNDERLYING THE INCREASINGLY RECOGNIZED ROLE OF ENVIRONMENTAL AND LIFESTYLE FACTORS IN HEALTH AND DISEASE AND THE INTERGENERATIONAL TRANSMISSION OF PHENOTYPES. RECENT STUDIES SUGGEST EPIGENETICS MAY BE CRITICAL IN VARIOUS DISEASES, FROM CARDIOVASCULAR DISEASE AND CANCER TO NEURODEVELOPMENTAL AND NEURODEGENERATIVE DISORDERS. EPIGENETIC MODIFICATIONS ARE POTENTIALLY REVERSIBLE AND COULD PROVIDE NEW THERAPEUTIC AVENUES FOR TREATING THESE DISEASES USING EPIGENETIC MODULATORS. MOREOVER, EPIGENETICS PROVIDE INSIGHT INTO DISEASE PATHOGENESIS AND BIOMARKERS FOR DISEASE DIAGNOSIS AND RISK STRATIFICATION. NEVERTHELESS, EPIGENETIC INTERVENTIONS HAVE THE POTENTIAL FOR UNINTENDED CONSEQUENCES AND MAY POTENTIALLY LEAD TO INCREASED RISKS OF UNEXPECTED OUTCOMES, SUCH AS ADVERSE DRUG REACTIONS, DEVELOPMENTAL ABNORMALITIES, AND CANCER. THEREFORE, RIGOROUS STUDIES ARE ESSENTIAL TO MINIMIZE THE RISKS ASSOCIATED WITH EPIGENETIC THERAPIES AND TO DEVELOP SAFE AND EFFECTIVE INTERVENTIONS FOR IMPROVING HUMAN HEALTH. THIS ARTICLE PROVIDES A SYNTHETIC AND HISTORICAL VIEW OF THE ORIGIN OF EPIGENETICS AND SOME OF THE MOST RELEVANT ACHIEVEMENTS. 2023 16 610 32 BEYOND THE GENOME: EPIGENETIC MECHANISMS IN LUNG REMODELING. THE LUNG DEVELOPS FROM A VERY SIMPLE OUTPOUCHING OF THE FOREGUT INTO A HIGHLY COMPLEX, FINELY STRUCTURED ORGAN WITH MULTIPLE SPECIALIZED CELL TYPES THAT ARE REQUIRED FOR ITS NORMAL PHYSIOLOGICAL FUNCTION. DURING BOTH THE DEVELOPMENT OF THE LUNG AND ITS REMODELING IN THE CONTEXT OF DISEASE OR RESPONSE TO INJURY, GENE EXPRESSION MUST BE ACTIVATED AND SILENCED IN A COORDINATED MANNER TO ACHIEVE THE TREMENDOUS PHENOTYPIC HETEROGENEITY OF CELL TYPES REQUIRED FOR HOMEOSTASIS AND PATHOGENESIS. EPIGENETIC MECHANISMS, CONSISTING OF DNA BASE MODIFICATIONS SUCH AS METHYLATION, ALTERATION OF HISTONES RESULTING IN CHROMATIN MODIFICATION, AND THE ACTION OF NONCODING RNA, CONTROL THE REGULATION OF INFORMATION "BEYOND THE GENOME" REQUIRED FOR BOTH LUNG MODELING AND REMODELING. EPIGENETIC REGULATION IS SUBJECT TO MODIFICATION BY ENVIRONMENTAL STIMULI, SUCH AS OXIDATIVE STRESS, INFECTION, AND AGING, AND IS THUS CRITICALLY IMPORTANT IN CHRONIC REMODELING DISORDERS SUCH AS IDIOPATHIC PULMONARY FIBROSIS (IPF), CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BRONCHOPULMONARY DYSPLASIA (BPD), AND PULMONARY HYPERTENSION (PH). TECHNOLOGICAL ADVANCES HAVE MADE IT POSSIBLE TO EVALUATE GENOME-WIDE EPIGENETIC CHANGES (EPIGENOMICS) IN DISEASES OF LUNG REMODELING, CLARIFYING EXISTING PATHOPHYSIOLOGICAL PARADIGMS AND UNCOVERING NOVEL MECHANISMS OF DISEASE. MANY OF THESE REPRESENT NEW THERAPEUTIC TARGETS. ADVANCES IN EPIGENOMIC TECHNOLOGY WILL ACCELERATE OUR UNDERSTANDING OF LUNG DEVELOPMENT AND REMODELING, AND LEAD TO NOVEL TREATMENTS FOR CHRONIC LUNG DISEASES. 2014 17 2162 30 EPIGENETIC MECHANISMS IN COPD: IMPLICATIONS FOR PATHOGENESIS AND DRUG DISCOVERY. INTRODUCTION: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IS THE FOURTH LEADING CAUSE OF DEATH WORLDWIDE. THE GROWING BURDEN OF COPD IS DUE TO CONTINUOUS TOBACCO USE, WHICH IS THE MOST IMPORTANT RISK FACTOR OF THE DISEASE, INDOOR FUMES, OCCUPATIONAL EXPOSURES AND ALSO AGING OF THE WORLD'S POPULATION. EPIGENETIC MECHANISMS SIGNIFICANTLY CONTRIBUTE TO COPD PATHOPHYSIOLOGY. AREAS COVERED: THIS REVIEW FOCUSES ON DISEASE-RELEVANT CHANGES IN DNA MODIFICATION, HISTONE MODIFICATION AND NON-CODING RNA EXPRESSION IN COPD, AND PROVIDES INSIGHT INTO NOVEL THERAPEUTIC APPROACHES MODULATING EPIGENETIC MECHANISMS. RECENT FINDINGS REVEALED, AMONG OTHERS, GLOBALLY CHANGED DNA METHYLATION PATTERNS, DECREASED LEVELS OF HISTONE DEACETYLASES AND REDUCED MICRORNAS LEVELS IN COPD. THE AUTHORS ALSO DISCUSS A POTENTIAL ROLE OF THE CHROMATIN SILENCING POLYCOMB GROUP OF PROTEINS IN COPD. EXPERT OPINION: COPD IS A HIGHLY COMPLEX DISEASE AND THERAPY DEVELOPMENT IS COMPLICATED BY THE FACT THAT MANY SMOKERS DEVELOP BOTH COPD AND LUNG CANCER. OF INTEREST, COMBINATION THERAPIES INVOLVING DNA METHYLTRANSFERASE INHIBITORS AND ANTI-INFLAMMATORY DRUGS PROVIDE A PROMISING APPROACH, AS THEY MIGHT BE THERAPEUTIC FOR BOTH COPD AND CANCER. ALTHOUGH THE FIELD OF EPIGENETIC RESEARCH HAS VIRTUALLY EXPLODED OVER THE LAST 10 YEARS, PARTICULAR EFFORTS ARE REQUIRED TO ENHANCE OUR KNOWLEDGE OF THE COPD EPIGENOME IN ORDER TO SUCCESSFULLY ESTABLISH EPIGENETIC-BASED THERAPIES FOR THIS WIDESPREAD DISEASE. 2014 18 3028 29 GENETICS OF COMPLEX AIRWAY DISEASE. THE PAST 3 YEARS HAVE SEEN HIGHLY SIGNIFICANT GENETIC EFFECTS IDENTIFIED FOR A WIDE VARIETY OF COMMON COMPLEX DISEASES, INCLUDING THE AIRWAY DISORDERS OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE. IT APPEARS THAT ONLY A PORTION OF THE GENETICALLY MEDIATED SUSCEPTIBILITY TO COMPLEX DISEASES HAS BEEN IDENTIFIED, AND THERE IS MUCH LEFT TO BE DISCOVERED. THIS REVIEW BRIEFLY DESCRIBES THE RESULTS OF THE GENOME-WIDE ASSOCIATION STUDIES OF ASTHMA AND GIVES AN OVERVIEW OF THE PARALLEL AND INCREASINGLY LARGE-SCALE STUDIES THAT ARE TAKING PLACE WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. THE FUTURE IMPACT IS DISCUSSED OF TECHNOLOGICAL ADVANCES THAT ALLOW INCREASINGLY LARGE-SCALE GENE EXPRESSION STUDIES, NEXT-GENERATION SEQUENCING, AND GENOME-WIDE TESTING FOR EPIGENETIC EFFECTS. THE USE OF GENETIC TECHNOLOGY TO EXAMINE THE AIRWAY MICROBIOTA THAT INTERACT WITH THE MUCOSA IN HEALTH AND DISEASE IS DESCRIBED. 2011 19 2526 35 EPIGENETICS APPLIED TO PSYCHIATRY: CLINICAL OPPORTUNITIES AND FUTURE CHALLENGES. PSYCHIATRIC DISORDERS ARE CLINICALLY HETEROGENEOUS AND DEBILITATING CHRONIC DISEASES RESULTING FROM A COMPLEX INTERPLAY BETWEEN GENE VARIANTS AND ENVIRONMENTAL FACTORS. EPIGENETIC PROCESSES, SUCH AS DNA METHYLATION AND HISTONE POSTTRANSLATIONAL MODIFICATIONS, INSTRUCT THE CELL/TISSUE TO CORRECTLY INTERPRET EXTERNAL SIGNALS AND ADJUST ITS FUNCTIONS ACCORDINGLY. GIVEN THAT EPIGENETIC MODIFICATIONS ARE SENSITIVE TO ENVIRONMENT, STABLE, AND REVERSIBLE, EPIGENETIC STUDIES IN PSYCHIATRY COULD REPRESENT A PROMISING APPROACH TO BETTER UNDERSTANDING AND TREATING DISEASE. IN THE PRESENT REVIEW, WE AIM TO DISCUSS THE CLINICAL OPPORTUNITIES AND CHALLENGES ARISING FROM THE EPIGENETIC RESEARCH IN PSYCHIATRY. USING SELECTED EXAMPLES, WE FIRST RECAPITULATE KEY FINDINGS SUPPORTING THE ROLE OF ADVERSE LIFE EVENTS, ALONE OR IN COMBINATION WITH GENETIC RISK, IN EPIGENETIC PROGRAMMING OF NEUROPSYCHIATRIC SYSTEMS. EPIGENETIC STUDIES FURTHER REPORT ENCOURAGING FINDINGS ABOUT THE USE OF METHYLATION CHANGES AS DIAGNOSTIC MARKERS OF DISEASE PHENOTYPE AND PREDICTIVE TOOLS OF PROGRESSION AND RESPONSE TO TREATMENT. THEN WE DISCUSS THE POTENTIAL OF USING TARGETED EPIGENETIC PHARMACOTHERAPY, COMBINED WITH PSYCHOSOCIAL INTERVENTIONS, FOR FUTURE PERSONALIZED MEDICINE FOR PATIENTS. FINALLY, WE REVIEW THE METHODOLOGICAL LIMITATIONS THAT COULD HINDER INTERPRETATION OF EPIGENETIC DATA IN PSYCHIATRY. THEY MAINLY ARISE FROM HETEROGENEITY AT THE INDIVIDUAL AND TISSUE LEVEL AND REQUIRE FUTURE STRATEGIES IN ORDER TO REINFORCE THE BIOLOGICAL RELEVANCE OF EPIGENETIC DATA AND ITS TRANSLATIONAL USE IN PSYCHIATRY. OVERALL, WE SUGGEST THAT EPIGENETICS COULD PROVIDE NEW INSIGHTS INTO A MORE COMPREHENSIVE INTERPRETATION OF MENTAL ILLNESS AND MIGHT EVENTUALLY IMPROVE THE NOSOLOGY, TREATMENT, AND PREVENTION OF PSYCHIATRIC DISORDERS. 2018 20 2657 24 EPITHELIAL DYSFUNCTION IN CHRONIC RESPIRATORY DISEASES, A SHARED ENDOTYPE? PURPOSE OF REVIEW: EPITHELIAL BARRIER DEFECTS ARE BEING APPRECIATED IN VARIOUS INFLAMMATORY DISORDERS; HOWEVER, CAUSAL UNDERLYING MECHANISMS ARE LACKING. IN THIS REVIEW, WE DESCRIBE THE DISRUPTION OF THE AIRWAY EPITHELIUM WITH REGARD TO UPPER AND LOWER AIRWAY DISEASES, THE ROLE OF EPIGENETIC ALTERATIONS UNDERLYING THIS PROCESS, AND POTENTIAL NOVEL WAYS OF INTERFERING WITH DYSFUNCTIONAL EPITHELIAL BARRIERS AS A NOVEL THERAPEUTIC APPROACH. RECENT FINDINGS: A DEFECTIVE EPITHELIAL BARRIER, IMPAIRED INNATE DEFENCE MECHANISMS OR HAMPERED EPITHELIAL CELL RENEWAL ARE FOUND IN UPPER AND LOWER AIRWAY DISEASES. BARRIER DYSFUNCTION MIGHT FACILITATE THE ENTRANCE OF FOREIGN SUBSTANCES, INITIATING AND FACILITATING THE ONSET OF DISEASE. LATEST DATA PROVIDED NOVEL INSIGHTS FOR POSSIBLE INVOLVEMENT OF EPIGENETIC ALTERATIONS INDUCED BY INFLAMMATION OR OTHER UNKNOWN MECHANISMS AS A POTENTIAL MECHANISM RESPONSIBLE FOR EPITHELIAL DEFECTS. ADDITIONALLY, THESE MECHANISMS MIGHT PRECEDE DISEASE DEVELOPMENT, AND REPRESENT A NOVEL THERAPEUTIC APPROACH FOR RESTORING EPITHELIAL DEFECTS. SUMMARY: A BETTER UNDERSTANDING OF THE ROLE OF EPIGENETICS IN DRIVING AND MAINTAINING EPITHELIAL DEFECTS IN VARIOUS INFLAMMATORY DISEASES, USING STATE-OF-THE-ART BIOLOGY TOOLS WILL BE CRUCIAL IN DESIGNING NOVEL THERAPIES TO PROTECT OR RECONSTITUTE A DEFECTIVE AIRWAY EPITHELIAL BARRIER. 2020